Vera Therapeutics to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Vera Therapeutics (Nasdaq: VERA) announced that management will present and hold one-on-one meetings at two investor conferences in early December 2025.

Events and logistics:

• Evercore Healthcare Conference — Fireside chat and 1x1s on Dec 2, 2025 at 8:45am ET in Coral Gables, FL; webcast: https://wsw.com/webcast/evercore52/vera/2362844
• Citi 2025 Global Healthcare Conference — Fireside chat and 1x1s on Dec 3, 2025 at 4:00pm ET in Miami, FL; webcast: https://kvgo.com/global-healthcare-conference-2025/vera-therapeutics-december-2025

A replay of the webcasts will be available for 90 days via the company’s Investor Calendar.

BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences.

Investor Conference Details:

• 8th Annual Evercore Healthcare Conference
  Format: Fireside Chat and 1x1s
  Webcast: https://wsw.com/webcast/evercore52/vera/2362844
  Date: Tuesday, December 2, 2025
  Time: 8:45am ET
  Location: Coral Gables, FL

• Citi 2025 Global Healthcare Conference
  Format: Fireside Chat and 1x1s
  Webcast: https://kvgo.com/global-healthcare-conference-2025/vera-therapeutics-december-2025
  Date: Wednesday, December 3, 2025
  Time: 4:00pm ET
  Location: Miami, FL

A replay of the webcasts will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.

About Vera Therapeutics
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics’ mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics’ lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both BAFF and APRIL, which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell–mediated diseases. Vera Therapeutics is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868. For more information, please visit www.veratx.com.

Forward-looking Statements
Statements contained in this press release regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the plans, commitments, aspirations and goals under the caption “About Vera Therapeutics”. Words such as “believe,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera Therapeutics’ business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics' filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

For more information, please contact:

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com

FAQ

When will Vera Therapeutics present at the Evercore Healthcare Conference (VERA)?

Vera will present on December 2, 2025 at 8:45am ET with a fireside chat and 1x1 meetings; a webcast is provided.

When is Vera Therapeutics scheduled to speak at the Citi 2025 Global Healthcare Conference (VERA)?

Vera is scheduled for a fireside chat and 1x1s on December 3, 2025 at 4:00pm ET; a webcast link is provided.

Where can investors watch the Vera Therapeutics investor conference webcasts (VERA)?

Webcasts are available at the listed conference URLs and a replay is posted in the company’s Investor Calendar for 90 days.

How long will Vera Therapeutics conference webcasts (VERA) be available for replay?

Replays will be available for 90 days and can be accessed via the Investor Calendar on the company website.

What formats will Vera Therapeutics use at the December 2025 conferences (VERA)?

Management will participate in a fireside chat and conduct one-on-one (1x1) investor meetings at both events.